C4 Therapeutics, Inc. presented clinical data from the ongoing Phase 1 dose escalation portion of its Phase 1/2 clinical trial of CFT7455, a MonoDAC?? degrader of IKZF1/3, for the potential treatment.
C4 Therapeutics Announces Positive Data from CFT7455 Phase 1 Trial in Relapsed/Refractory Multiple Myeloma tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.
COMICS SHIPPING THIS WEEK firstcomicsnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from firstcomicsnews.com Daily Mail and Mail on Sunday newspapers.
About Emera We re a team of experts focused on building a cleaner energy future. Our Environmental, Social and Governance commitments are core. | April 12, 2023